436 related articles for article (PubMed ID: 38104104)
21. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
22. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
[TBL] [Abstract][Full Text] [Related]
23. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
24. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
Kosti P; Maher J; Arnold JN
Front Immunol; 2018; 9():1104. PubMed ID: 29872437
[TBL] [Abstract][Full Text] [Related]
25. Colorectal cysts as a validating tool for CAR therapy.
Dillard P; Lie M; Baken E; Lobert VH; Benard E; Köksal H; Inderberg EM; Wälchli S
BMC Biotechnol; 2020 Jun; 20(1):30. PubMed ID: 32487146
[TBL] [Abstract][Full Text] [Related]
26. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
[TBL] [Abstract][Full Text] [Related]
27. New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy.
Wu WT; Lin WY; Chen YW; Lin CF; Wang HH; Wu SH; Lee YY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673696
[TBL] [Abstract][Full Text] [Related]
28. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
29. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
Gumber D; Wang LD
EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
[TBL] [Abstract][Full Text] [Related]
30. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
31. Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer.
Kandra P; Nandigama R; Eul B; Huber M; Kobold S; Seeger W; Grimminger F; Savai R
Front Immunol; 2022; 13():903562. PubMed ID: 35720364
[TBL] [Abstract][Full Text] [Related]
32. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
33. Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain.
Herrera-Rios D; Mughal SS; Teuber-Hanselmann S; Pierscianek D; Sucker A; Jansen P; Schimming T; Klode J; Reifenberger J; Felsberg J; Keyvani K; Brors B; Sure U; Reifenberger G; Schadendorf D; Helfrich I
Front Immunol; 2020; 11():120. PubMed ID: 32117271
[TBL] [Abstract][Full Text] [Related]
34. Injectable and photocurable CAR-T cell formulation enhances the anti-tumor activity to melanoma in mice.
Zhou W; Lei S; Liu M; Li D; Huang Y; Hu X; Yang J; Li J; Fu M; Zhang M; Wang F; Li J; Men K; Wang W
Biomaterials; 2022 Dec; 291():121872. PubMed ID: 36323072
[TBL] [Abstract][Full Text] [Related]
35. CAR T Cell Therapy in Primary Brain Tumors: Current Investigations and the Future.
Lin YJ; Mashouf LA; Lim M
Front Immunol; 2022; 13():817296. PubMed ID: 35265074
[TBL] [Abstract][Full Text] [Related]
36. Beyond direct killing-novel cellular immunotherapeutic strategies to reshape the tumor microenvironment.
Huynh D; Winter P; Märkl F; Endres S; Kobold S
Semin Immunopathol; 2023 Mar; 45(2):215-227. PubMed ID: 36167831
[TBL] [Abstract][Full Text] [Related]
37. Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy.
Ginefra P; Lorusso G; Vannini N
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32580431
[TBL] [Abstract][Full Text] [Related]
38. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
[TBL] [Abstract][Full Text] [Related]
39. Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.
Koustas E; Trifylli EM; Sarantis P; Papadopoulos N; Karapedi E; Aloizos G; Damaskos C; Garmpis N; Garmpi A; Papavassiliou KA; Karamouzis MV; Papavassiliou AG
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743107
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects.
Bozorgi A; Bozorgi M; Khazaei M
Cell Oncol (Dordr); 2022 Oct; 45(5):755-777. PubMed ID: 35943716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]